Methotrexate for induction of remission in refractory Crohn's disease (Q24194453)

1

0 references

Yongjun Wang

2

0 references

David J Tsoulis

3

0 references

John K MacDonald

Cochrane Database of Systematic Reviews

4

0 references

publication date

6 August 2014

0 references

published in

0 references

cites work

Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003459.PUB4

Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003459.PUB4

Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003459.PUB4

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003459.PUB4

Methotrexate for Crohn's disease: experience in a district general hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003459.PUB4

Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003459.PUB4

Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003459.PUB4

Efficacy and tolerability of methotrexate therapy for refractory Crohn's disease: a large single-centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003459.PUB4

Low-dose oral methotrexate for maintaining Crohn's disease remission: where we stand

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003459.PUB4

Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003459.PUB4

Pharmacokinetics of subcutaneous methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003459.PUB4

Low-dose oral methotrexate in refractory inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003459.PUB4

Prognosis in Crohn's disease--based on results from a regional patient group from the county of Copenhagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003459.PUB4

Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003459.PUB4

Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003459.PUB4

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003459.PUB4

A simple index of Crohn's-disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003459.PUB4

Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003459.PUB4

Cyclosporine for induction of remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003459.PUB4

Methotrexate for induction of remission in refractory Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003459.PUB4

Methotrexate for induction of remission in refractory Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003459.PUB4

Methotrexate for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003459.PUB4

6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease

21 January 2018

1 reference

12 December 2020

Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis

1 reference

12 December 2020

Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology

1 reference

12 December 2020

[Methotrexate in therapy of chronic inflammatory bowel diseases]

1 reference

12 December 2020

Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial

1 reference

12 December 2020

Methotrexate in Crohn's disease: long-term efficacy and toxicity

1 reference

12 December 2020

[Methotrexate as possible treatment in refractory chronic inflammatory intestinal disease]

1 reference

12 December 2020

Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term?

1 reference

12 December 2020

Long-term methotrexate for Crohn's disease: safety and efficacy in clinical practice

1 reference

12 December 2020

A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis

1 reference

12 December 2020

Daily folate supplementation is adequate prophylaxis against methotrexate-induced nausea and vomiting and avoids the need for expensive anti-emetic prescription

1 reference

12 December 2020

Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020